Tarsus Pharmaceuticals has appointed former Allergan Chairman and CEO David Pyott to its board of directors, adding a seasoned eye care executive as the Irvine-based biotech firm advances its commercial strategy.
“David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact,” Tarsus CEO Bobak Azamian said in a statement released Wednesday. “His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth. We are honored to welcome him to our Board.”
Pyott led Allergan for 17 years, transforming it from a roughly $1 billion eye care company into a global specialty pharmaceutical and medical device maker generating more than $7 billion in revenue. He was previously named one of Harvard Business Review’s “100 Best Performing CEOs in the World.”
Tarsus, one of Orange County’s fastest-growing publicly traded companies, is the maker of Xdemvy — the first FDA-approved treatment for eyelid inflammation, Demodex blepharitis. The company plans to report fourth-quarter earnings on Monday, Feb. 23.
